

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel

The following applies to EPPAN / Comprehensive Epilepsy Gene Panel. Testing is performed to evaluate for the presence of variants in coding regions and extending to +/- 10 base pairs of adjacent intronic sequence on either side of the coding exons of the genes analyzed. In addition, the analysis will cover select non-coding variants. Next-generation sequencing and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of copy number variants (CNV) in the genes analyzed. A polymerase chain reaction-based assay is performed to test for the presence of CSTB dodecamer repeat expansions in addition to sequence variants and deletions/duplications. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

This document is intended to highlight additional evaluations for variants of high clinical interest as well as technical limitations. However, this document does not comprehensively reflect all genomic regions covered by this test. For questions regarding transcripts, or genes or regions covered, contact the laboratory at 800-533-1710.

Genomic Build: GRCh37 (hg19) unless otherwise specified

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>ABAT</i>	NM_020686.6	-	-
<i>ACO2</i>	NM_001098.3	-	-
<i>ACY1</i>	NM_000666.3	-	-
<i>ADARB1</i>	NM_015833.4	-	CNV analysis in Exon 8 will not be performed
<i>ADGRG1</i>	NM_005682.7	c.-153-2228 to c.-153-2178	-
<i>ADSL</i>	NM_000026.4	c.-54 to c.-44	-
<i>AFG3L2</i>	NM_006796.3	-	-
<i>AIFM1</i>	NM_004208.4	-	-
<i>AKT2</i>	NM_001626.6	-	-
<i>ALDH3A2</i>	NM_000382.3	-	-
<i>ALDH5A1</i>	NM_001080.3	-	-
<i>ALDH7A1</i>	NM_001182.5	-	-
<i>ALG13</i>	NM_001099922.3	-	-
<i>AMT</i>	NM_000481.4	-	-
<i>AP2M1</i>	NM_004068.4	-	-
<i>APOPT1 (COA8)</i>	NM_032374.4	-	-
<i>ARFGEF2</i>	NM_006420.3	-	-
<i>ARHGEF9</i>	NM_015185.3	-	-
<i>ARX</i>	NM_139058.3	-	-
<i>ASAH1</i>	NM_177924.5	-	CNV analysis in Exon 4 will not be performed
<i>ASNS</i>	NM_133436.3	-	-
<i>ATN1</i>	NM_001007026.2	-	-
<i>ATP1A2</i>	NM_000702.4	-	-
<i>ATP1A3</i>	NM_152296.5	-	-
<i>ATRX</i>	NM_000489.5	-	-
<i>BCKDK</i>	NM_005881.4	-	-
<i>BCS1L</i>	NM_004328.5	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>BOLA3</i>	NM_212552.3	-	-
<i>BRAT1</i>	NM_152743.4	-	-
<i>C12orf57</i>	NM_138425.4	-	-
<i>CACNA1A</i>	NM_001127221.1	-	-
<i>CACNA1E</i>	NM_000721.4	-	-
<i>CACNA2D2</i>	NM_006030.4	-	-
<i>CAD</i>	NM_004341.5	-	-
<i>CARS2</i>	NM_024537.4	-	-
<i>CASK</i>	NM_003688.3	-	CNV analysis in Exon 16 will not be performed
<i>CASK</i>	NM_001126055.2	-	CNV analysis in Exon 15 will not be performed
<i>CCM2</i>	NM_031443.3	-	-
<i>CDKL5</i>	NM_003159.2	-	CNV analysis in Exon 19 will not be performed
<i>CDKL5</i>	NM_001323289.2	c.-162-7 to c.-159	-
<i>CHD2</i>	NM_001271.4	-	-
<i>CHRNA2</i>	NM_000742.4	-	-
<i>CHRNA4</i>	NM_000744.6	-	-
<i>CHRNA2</i>	NM_000748.3	-	-
<i>CLCN4</i>	NM_001830.4	-	-
<i>CLN3</i>	NM_001042432.1	-	-
<i>CLN5</i>	NM_006493.4	-	-
<i>CLN6</i>	NM_017882.3	-	-
<i>CLN8</i>	NM_018941.4	-	-
<i>CNTNAP2</i>	NM_014141.6	-	-
<i>COA8 (APOPT1)</i>	NM_032374.4	-	-
<i>COG7</i>	NM_153603.4	-	-
<i>COG8</i>	NM_032382.4	-	-
<i>COL18A1</i>	ENST00000400337.6	-	CNV analysis in Exon 1 will not be performed
<i>COL4A1</i>	NM_001845.6	-	-
<i>COQ2</i>	NM_015697.8	-	-
<i>COQ4</i>	NM_016035.5	-	-
<i>COQ6</i>	NM_182476.3	-	-
<i>COQ8A</i>	NM_020247.5	-	-
<i>COQ9</i>	NM_020312.4	-	-
<i>COX10</i>	NM_001303.4	-	CNV analysis in Exon 6 will not be performed
<i>COX15</i>	NM_004376.7	-	CNV analysis in Exon 9 will not be performed
<i>CPT2</i>	NM_000098.3	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>CSF1R</i>	NM_005211.3	c.1969+126 to c.1969+105	-
<i>CSTB</i>	NM_000100.3	A polymerase chain reaction-based assay is utilized to detect CSTB dodecamer repeat expansions upstream of the gene region. c.168+32 to c.168+11	-
<i>CTSD</i>	NM_001909.5	-	-
<i>CTSF</i>	NM_003793.4	-	-
<i>CUL4B</i>	NM_003588.3	-	-
<i>D2HGDH</i>	NM_152783.5	-	-
<i>DCX</i>	NM_178153.3	-	-
<i>DDC</i>	NM_000790.4	-	-
<i>DDX3X</i>	NM_001193416.3	-	-
<i>DEPDC5</i>	NM_001242896.3	-	-
<i>DHFR</i>	NM_000791.4	-	CNV analysis in Exon 6 will not be performed
<i>DIAPH1</i>	NM_005219.5	-	-
<i>DLD</i>	NM_000108.5	-	-
<i>DMXL2</i>	NM_001174116.2	-	-
<i>DNAJC5</i>	NM_025219.3	-	-
<i>DNM1</i>	NM_004408.4	-	-
<i>DNM1L</i>	NM_012062.5	-	-
<i>DOCK7</i>	NM_001271999.1	-	-
<i>DYRK1A</i>	NM_001396.4	-	-
<i>EARS2</i>	NM_001083614.2	-	-
<i>EEF1A2</i>	NM_001958.5	-	-
<i>EHMT1</i>	NM_024757.5	-	CNV analysis in Exon 1 will not be performed
<i>EIF2AK2</i>	NM_001135651.3	-	-
<i>EPM2A</i>	NM_005670.4	-	-
<i>ETHE1</i>	NM_014297.5	-	-
<i>FARS2</i>	NM_006567.5	-	-
<i>FASTKD2</i>	NM_014929.3	-	-
<i>FBP1</i>	NM_000507.4	-	-
<i>FBXL4</i>	NM_012160.4	-	-
<i>FH</i>	NM_000143.3	-	-
<i>FKRP</i>	NM_024301.5	-	-
<i>FKTN</i>	NM_001079802.1	c.648-1248 to c.648-1238	-
<i>FLNA</i>	NM_001456.3	-	-
<i>FOLR1</i>	NM_016725.3	-	-
<i>FOXP1</i>	NM_005249.5	-	-
<i>FOXRED1</i>	NM_017547.4	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>FRRS1L</i>	NM_014334.3	-	-
<i>GABBR2</i>	NM_005458.8	-	-
<i>GABRA1</i>	NM_000806.5	-	-
<i>GABRB2</i>	NM_021911.2	-	CNV analysis in Exon 10 will not be performed
<i>GABRB3</i>	NM_000814.6	-	-
<i>GABRG2</i>	NM_000816.3	-	-
<i>GAMT</i>	NM_000156.6	-	-
<i>GATM</i>	NM_001482.3	-	-
<i>GCK</i>	NM_000162.5	-	-
<i>GFM1</i>	NM_024996.5	-	-
<i>GLDC</i>	NM_000170.2	-	-
<i>GLRA1</i>	NM_000171.4	-	-
<i>GLUL</i>	NM_002065.6	-	-
<i>GNAO1</i>	NM_020988.3	-	CNV analysis in Exon 2 will not be performed
<i>GOSR2</i>	NM_004287.4	-	CNV analysis in Exon 2 will not be performed
<i>GPAA1</i>	NM_003801.4	-	-
<i>GPC3</i>	NM_004484.4	-	-
<i>GPHN</i>	NM_020806.4	-	-
<i>GRIA3</i>	NM_000828.4	-	-
<i>GRIN1</i>	NM_007327.4	-	-
<i>GRIN2A</i>	NM_000833.5	-	-
<i>GRIN2B</i>	NM_000834.4	-	-
<i>GYS2</i>	NM_021957.4	-	-
<i>HCFC1</i>	NM_005334.3	-	-
<i>HCN1</i>	NM_021072.4	-	-
<i>HIBCH</i>	NM_014362.4	-	-
<i>HNRNPU</i>	NM_031844.3	-	-
<i>HSD17B10</i>	NM_004493.3	-	-
<i>IARS2</i>	NM_018060.4	-	-
<i>IBA57</i>	NM_001010867.4	-	-
<i>IDH2</i>	NM_002168.3	-	-
<i>IER3IP1</i>	NM_016097.5	-	-
<i>IQSEC2</i>	NM_001111125.3	-	-
<i>ITPA</i>	NM_033453.4	-	-
<i>KANSL1</i>	NM_001193466.2	-	CNV analysis in Exon 2, Exon 3 will not be performed
<i>KCNA1</i>	NM_000217.3	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>KCNA2</i>	NM_004974.4	-	-
<i>KCNB1</i>	NM_004975.4	-	-
<i>KCNC1</i>	NM_001112741.1	-	-
<i>KCNH1</i>	NM_172362.3	-	-
<i>KCNJ10</i>	NM_002241.5	-	-
<i>KCNMA1</i>	NM_002247.4	-	-
<i>KCNMA1</i>	NM_001271520.2	-	-
<i>KCNQ2</i>	NM_172107.4	-	-
<i>KCNQ3</i>	NM_004519.4	-	-
<i>KCNT1</i>	NM_020822.3	-	-
<i>KCTD7</i>	NM_153033.4	-	-
<i>KDM5C</i>	NM_004187.4	-	-
<i>KDM6A</i>	NM_021140.3	-	-
<i>KRIT1</i>	NM_194456.1	-	-
<i>L2HGDH</i>	NM_024884.3	-	CNV analysis in Exon 6 will not be performed
<i>LAMA2</i>	NM_000426.3	-	-
<i>LARGE1</i>	NM_004737.6	-	-
<i>LGI1</i>	NM_005097.4	-	-
<i>LIAS</i>	NM_006859.4	-	-
<i>LRPPRC</i>	NM_133259.4	-	CNV analysis in Exon 19, Exon 36, Exon 38 will not be performed
<i>MBD5</i>	NM_018328.4	-	-
<i>MECP2</i>	NM_004992.3	-	-
<i>MECP2</i>	NM_001110792.2	-	-
<i>MEF2C</i>	NM_002397.5	-	-
<i>MFSD8</i>	NM_152778.3	-	-
<i>MICU1</i>	NM_006077.3	-	-
<i>MOCS1</i>	NM_005943.5	c.*7+10 to c.*7+1	-
<i>MOCS2</i>	NM_176806.4	-	-
<i>MOCS2</i>	NM_004531.5	-	-
<i>MTFMT</i>	NM_139242.4	-	-
<i>MTO1</i>	NM_012123.4	-	-
<i>MTOR</i>	NM_004958.4	-	-
<i>NALCN</i>	NM_052867.4	-	-
<i>NDUFA1</i>	NM_004541.4	-	-
<i>NDUFA2</i>	NM_002488.4	-	-
<i>NDUFAF2</i>	NM_174889.5	-	-
<i>NDUFAF3</i>	NM_199069.2	-	-
<i>NDUFAF4</i>	NM_014165.4	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>NDUFAF5</i>	NM_024120.5	-	-
<i>NDUFAF6</i>	NM_152416.4	c.420+779 to c.420+789	-
<i>NDUFS1</i>	NM_005006.7	-	-
<i>NDUFS4</i>	NM_002495.4	-	-
<i>NDUFS6</i>	NM_004553.5	-	-
<i>NDUFS7</i>	NM_024407.5	-	-
<i>NDUFS8</i>	NM_002496.4	-	-
<i>NDUFV1</i>	NM_007103.4	-	-
<i>NECAP1</i>	NM_015509.4	-	-
<i>NEDD4L</i>	NM_015277.6	-	CNV analysis in Exon 4, Exon 26 will not be performed
<i>NEU1</i>	NM_000434.4	-	-
<i>NEXMIF</i>	NM_001008537.3	-	-
<i>NGLY1</i>	NM_018297.4	-	-
<i>NHLRC1</i>	NM_198586.3	-	-
<i>NOTCH3</i>	NM_000435.3	-	-
<i>NPRL2</i>	NM_006545.5	-	-
<i>NPRL3</i>	NM_001077350.3 [GRCh38(hg38)]	-	-
<i>NR2F1</i>	NM_005654.6	-	-
<i>NR4A2</i>	NM_006186.4	-	-
<i>NRROS</i>	NM_198565.3	-	-
<i>NRXN1</i>	NM_001135659.2	-	CNV analysis in Exon 6, Exon 13 will not be performed
<i>OCLN</i>	NM_002538.4	-	Sequencing and CNV analysis in Exon 5 - Exon 9 will not be performed
<i>OFD1</i>	NM_003611.3	-	-
<i>OPHN1</i>	NM_002547.3	-	-
<i>OTUD6B</i>	NM_016023.5	-	-
<i>P4HTM</i>	NM_177938.2	-	-
<i>PACS1</i>	NM_018026.4	-	-
<i>PACS2</i>	NM_001100913.3	-	-
<i>PAFAH1B1</i>	NM_000430.4	-	CNV analysis in Exon 4 will not be performed
<i>PAK3</i>	NM_002578.5	-	CNV analysis in Exon 11 will not be performed
<i>PCDH12</i>	NM_016580.3	-	-
<i>PCDH19</i>	NM_001184880.2	-	-
<i>PDCD10</i>	NM_145860.1	-	-
<i>PDHA1</i>	NM_000284.4	c.292-28 to c.292-18	-
<i>PDHB</i>	NM_000925.4	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>PDHX</i>	NM_003477.3	-	-
<i>PDP1</i>	NM_018444.4	-	-
<i>PDSS2</i>	NM_020381.4	-	CNV analysis in Exon 7 will not be performed
<i>PEX7</i>	NM_000288.4	c.-50 to c.-40	-
<i>PHF6</i>	NM_032458.3	-	-
<i>PHGDH</i>	NM_006623.4	-	-
<i>PIGA</i>	NM_002641.3	-	-
<i>PIGG</i>	NM_001127178.3	-	-
<i>PIGK</i>	NM_005482.3	-	-
<i>PIGL</i>	NM_004278.4	-	-
<i>PIGM</i>	NM_145167.3	c.-265 to c.-275	-
<i>PIGN</i>	NM_176787.5	-	CNV analysis in Exon 14 will not be performed
<i>PIGO</i>	NM_032634.4	-	-
<i>PIGQ</i>	NM_004204.4	-	-
<i>PIGS</i>	NM_033198.4	-	-
<i>PIGT</i>	NM_015937.6	-	-
<i>PIGU</i>	NM_080476.4	-	-
<i>PIGV</i>	NM_017837.3	-	-
<i>PIGW</i>	NM_178517.4	-	-
<i>PLCB1</i>	NM_015192.4	-	-
<i>PLP1</i>	NM_000533.5	c.453+16 to c.453+54; c.453+154 to c.453+169; c.454-327 to c.454-307	-
<i>PLPBP</i>	NM_007198.4	-	-
<i>PNKP</i>	NM_007254.4	c.1387-23 to c.1386+39	-
<i>PNPLA8</i>	NM_015723.5	-	-
<i>PNPO</i>	NM_018129.4	-	-
<i>POLG</i>	NM_002693.2	-	-
<i>POMGNT1</i>	NM_017739.3	-	-
<i>POMT1</i>	NM_007171.3	-	-
<i>POMT2</i>	NM_013382.5	c.1333-11 to c.1333-19	-
<i>PPP2R5D</i>	NM_006245.4	-	-
<i>PPT1</i>	NM_000310.3	-	-
<i>PRRT2</i>	NM_145239.3	-	-
<i>PURA</i>	NM_005859.5	-	-
<i>QARS1</i>	NM_005051.3	-	-
<i>RAB39B</i>	NM_171998.4	-	-
<i>RAB3GAP1</i>	NM_012233.3	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>RALA</i>	NM_005402.4	-	-
<i>RALGAP1</i>	NM_014990.3	-	CNV analysis in Exon 4, Exon 5, Exon 24, Exon 33 will not be performed
<i>RANBP2</i>	NM_006267.5	-	Sequencing and CNV analysis in Exon 2 - Exon 20 will not be performed
<i>RARS2</i>	NM_020320.5	-	-
<i>RELN</i>	NM_005045.4	-	CNV analysis in Exon 37, Exon 64 will not be performed
<i>RMND1</i>	NM_017909.4	-	-
<i>ROGDI</i>	NM_024589.2	-	-
<i>RRM2B</i>	NM_015713.5	-	-
<i>SATB2</i>	NM_015265.4	-	-
<i>SCARB2</i>	NM_005506.4	-	-
<i>SCN1A</i>	NM_001165963.3	c.4002+2508 to c.4002+2158; c.265-2138 to c.265-2148	-
<i>SCN1B</i>	NM_001037.5	-	CNV analysis in Exon 1 will not be performed
<i>SCN2A</i>	NM_021007.3	-	-
<i>SCN2A</i>	NM_001040143.2	-	-
<i>SCN3A</i>	NM_006922.4	-	-
<i>SCN8A</i>	NM_014191.4	-	-
<i>SCN8A</i>	NM_001330260.2	-	-
<i>SCO2</i>	NM_005138.2	-	-
<i>SDHAF1</i>	NM_001042631.2	-	-
<i>SERAC1</i>	NM_032861.4	-	CNV analysis in Exon 3 will not be performed
<i>SERPINI1</i>	NM_005025.4	-	-
<i>SETBP1</i>	NM_015559.3	-	-
<i>SETD2</i>	NM_014159.6	-	CNV analysis in Exon 2 will not be performed
<i>SIK1</i>	NM_173354.5	-	-
<i>SLC12A5</i>	NM_020708.5	-	-
<i>SLC13A5</i>	NM_177550.5	-	-
<i>SLC16A1</i>	NM_003051.3	-	-
<i>SLC19A3</i>	NM_025243.4	c.980-11 to c.980-19	-
<i>SLC25A1</i>	NM_005984.5	-	-
<i>SLC25A12</i>	NM_003705.5	-	-
<i>SLC25A22</i>	NM_024698.6	-	-
<i>SLC2A1</i>	NM_006516.3	c.680-11 to c.680-16	-
<i>SLC35A2</i>	NM_001042498.3	-	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>SLC35A3</i>	NM_012243.3	-	CNV analysis in Exon 6 will not be performed
<i>SLC6A1</i>	NM_003042.4	-	-
<i>SLC6A8</i>	NM_005629.4	-	-
<i>SLC9A6</i>	NM_006359.3	-	-
<i>SLC9A6</i>	NM_001042537.1	-	-
<i>SMARCA2</i>	NM_003070.5	-	-
<i>SMC1A</i>	NM_006306.4	-	-
<i>SMS</i>	NM_004595.5	-	-
<i>SNAP25</i>	NM_003081.4	-	-
<i>SNAP25</i>	NM_130811.3	-	-
<i>SNAP29</i>	NM_004782.4	-	-
<i>SNX27</i>	NM_030918.6	-	-
<i>SPATA5</i>	NM_145207.3	-	-
<i>SPR</i>	NM_003124.5	-	-
<i>SPTAN1</i>	NM_001130438.3	-	-
<i>ST3GAL3</i>	NM_006279.5	-	-
<i>ST3GAL5</i>	NM_003896.4	-	-
<i>STRADA</i>	NM_001003787.4	-	-
<i>STX1B</i>	NM_052874.5	-	-
<i>STXBP1</i>	NM_003165.4	-	-
<i>STXBP1</i>	NM_001032221.4	-	-
<i>SUCLA2</i>	NM_003850.2	-	-
<i>SUOX</i>	NM_000456.3	-	-
<i>SYN1</i>	NM_133499.2	-	-
<i>SYNGAP1</i>	NM_006772.3	-	CNV analysis in Exon 14 will not be performed
<i>SYNJ1</i>	NM_003895.3	-	-
<i>SYP</i>	NM_003179.2	-	-
<i>SZT2</i>	NM_015284.4	-	-
<i>TBC1D24</i>	NM_001199107.2	-	-
<i>TBL1XR1</i>	NM_024665.6	-	-
<i>TCF4</i>	NM_001083962.2	-	-
<i>TPK1</i>	NM_022445.4	-	-
<i>TPP1</i>	NM_000391.4	-	-
<i>TSC1</i>	NM_000368.5	-	-
<i>TSC2</i>	NM_000548.5	c.848+276 to c.848+286; c.976-20 to c.976-11; c.2838-127 to c.2838-117; c.5069-22 to c.5069-13; c.5259+11 to c.5259+29	-

Targeted Genes and Methodology Details for Comprehensive Epilepsy With or Without Encephalopathy Gene Panel (continued)

Gene	Reference Transcript ^a	Additional Evaluations	Technical Limitations
<i>TSFM</i>	NM_001172696.2	-	CNV analysis in Exon 5 will not be performed
<i>TUBA1A</i>	NM_006009.4	-	-
<i>TUBA8</i>	NM_018943.3	-	-
<i>TUBB2B</i>	NM_178012.5	-	CNV analysis in Exon 4 will not be performed
<i>TWINK</i>	NM_021830.5	-	-
<i>UBE3A</i>	NM_130838.4	-	-
<i>UGP2</i>	NM_006759.3	-	-
<i>USP7</i>	NM_003470.3	-	-
<i>VAR2</i>	NM_001167734.1	-	-
<i>VLDLR</i>	NM_003383.5	-	-
<i>WDR26</i>	NM_025160.6	-	-
<i>WDR37</i>	NM_014023.4	-	-
<i>WDR45</i>	NM_007075.3	-	-
<i>WDR62</i>	NM_001083961.2	-	-
<i>WWOX</i>	NM_016373.4	-	-
<i>YWHAG</i>	NM_012479.4	-	-
<i>ZDHC9</i>	NM_016032.4	-	-
<i>ZEB2</i>	NM_014795.4	-	-